Mahantshetty U, Poetter R, Beriwal S, Grover S, Lavanya G, Rai B
Radiother Oncol. 2021; 160:273-284.
PMID: 34019918
PMC: 8675891.
DOI: 10.1016/j.radonc.2021.05.010.
Kido A, Nakamoto Y
Br J Radiol. 2021; 94(1125):20201342.
PMID: 33989030
PMC: 9327757.
DOI: 10.1259/bjr.20201342.
Olpin J, Chuang L, Berek J, Gaffney D
Gynecol Oncol Rep. 2018; 25:115-121.
PMID: 30094311
PMC: 6072969.
DOI: 10.1016/j.gore.2018.07.001.
McEvoy S, Nougaret S, Abu-Rustum N, Vargas H, Sadowski E, Menias C
Abdom Radiol (NY). 2017; 42(10):2488-2512.
PMID: 28528388
PMC: 5857967.
DOI: 10.1007/s00261-017-1179-3.
Gardner C, Sunil J, Klopp A, Devine C, Sagebiel T, Viswanathan C
Br J Radiol. 2015; 88(1052):20150033.
PMID: 25966291
PMC: 4651370.
DOI: 10.1259/bjr.20150033.
Usefulness of F-18 FDG PET/CT in Assessment of Recurrence of Cervical Cancer After Treatment.
Lee M, Lee Y, Hwang K, Choe W, Park C
Nucl Med Mol Imaging. 2014; 45(2):111-6.
PMID: 24899989
PMC: 4043016.
DOI: 10.1007/s13139-010-0059-3.
Role of F-18 fluorodeoxyglucose positron emission tomography/computed tomography in the detection of recurrence in patients with cervical cancer.
Bhoil A, Mittal B, Bhattacharya A, Santhosh S, Patel F
Indian J Nucl Med. 2014; 28(4):216-20.
PMID: 24379531
PMC: 3866666.
DOI: 10.4103/0972-3919.121966.
Evaluation of microscopic tumor extension in early-stage cervical cancer: quantifying subclinical uncertainties by pathological and magnetic resonance imaging findings.
Sanuki N, Urabe S, Matsumoto H, Ono A, Komatsu E, Kamei N
J Radiat Res. 2013; 54(4):719-26.
PMID: 23381955
PMC: 3709675.
DOI: 10.1093/jrr/rrt004.
Imaging of endometrial and cervical cancer.
Patel S, Liyanage S, Sahdev A, Rockall A, Reznek R
Insights Imaging. 2012; 1(5-6):309-328.
PMID: 22347925
PMC: 3259382.
DOI: 10.1007/s13244-010-0042-7.
Imaging of female pelvic malignancies regarding MRI, CT, and PET/CT: Part 2.
Alt C, Brocker K, Eichbaum M, Sohn C, Arnegger F, Kauczor H
Strahlenther Onkol. 2011; 187(11):705-14.
PMID: 22037656
DOI: 10.1007/s00066-011-4002-z.
Imaging of female pelvic malignancies regarding MRI, CT, and PET/CT : part 1.
Brocker K, Alt C, Eichbaum M, Sohn C, Kauczor H, Hallscheidt P
Strahlenther Onkol. 2011; 187(10):611-8.
PMID: 21947126
DOI: 10.1007/s00066-011-4001-0.
Comparison of T2-weighted and contrast-enhanced T1-weighted MR imaging at 1.5 T for assessing the local extent of cervical carcinoma.
Akita A, Shinmoto H, Hayashi S, Akita H, Fujii T, Mikami S
Eur Radiol. 2011; 21(9):1850-7.
PMID: 21479769
DOI: 10.1007/s00330-011-2122-6.
Clinical significance of tumor volume and lymph node involvement assessed by MRI in stage IIB cervical cancer patients treated with concurrent chemoradiation therapy.
Lee D, Kim Y, Kim J, Kim S, Kim S, Nam E
J Gynecol Oncol. 2010; 21(1):18-23.
PMID: 20379443
PMC: 2849943.
DOI: 10.3802/jgo.2010.21.1.18.
Efficacy of 18F-FDG PET/CT in the evaluation of patients with recurrent cervical carcinoma.
Mittra E, El-Maghraby T, Rodriguez C, Quon A, McDougall I, Gambhir S
Eur J Nucl Med Mol Imaging. 2009; 36(12):1952-9.
PMID: 19585114
PMC: 4157596.
DOI: 10.1007/s00259-009-1206-x.
Classical tandem-source dwelling covering the entire uterus: essential in modern intracavitary radiotherapy for cervical cancer?.
Ohara K, Nemoto K, Ohnishi K, Hashimoto T, Fukumitsu N, Hata M
Radiat Med. 2007; 25(8):386-92.
PMID: 17952542
DOI: 10.1007/s11604-007-0154-2.
Magnetic resonance imaging of the cervix.
Zand K, Reinhold C, Abe H, Maheshwari S, Mohamed A, Upegui D
Cancer Imaging. 2007; 7:69-76.
PMID: 17535778
PMC: 1931514.
DOI: 10.1102/1470-7330.2007.0011.
Cervical cancer: MR imaging findings before, during, and after radiation therapy.
Engin G
Eur Radiol. 2006; 16(2):313-24.
PMID: 16425027
DOI: 10.1007/s00330-005-2804-z.
